CDK12 and Familial prostate cancer: Surprisingly, CDK12 mutation frequency in prostate cancer showed a significantly higher rate in Chinese patients,26, 33 with 15.4%−27.2% compared to approximately 4.7% among global prostate cancer patients (Figure 1D).